Optimi Health Corp.

Equities

OPTI

CA68405H1001

Other Specialty Retailers

Market Closed - Canadian Securities Exchange 03:48:03 2024-04-18 pm EDT 5-day change 1st Jan Change
0.26 CAD +1.96% Intraday chart for Optimi Health Corp. +4.00% +6.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient CI
Optimi Health Corp. Signs Psilocybin Supply Agreement with Matai Medical Research Institute CI
Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract CI
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University MT
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University CI
Optimi Health Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
492,000 Warrants of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024. CI
606,000 Options of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024. CI
3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024. CI
Optimi Health Notes Lykos Therapeutics and FDA Priority Review of New Drug Application MT
Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding CI
Optimi Health Corp. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Optimi Health Secures Amendment to Increase Quantities of MDMA, MDA, and 2C-B MT
Optimi Health Granted Precursor Licence to Formulate MDMA, Completes Encapsulation Of Two Dosage Formats MT
Sunshine Earth Labs Ltd. and Optimi Health Corp. Announce Strategic Supply Agreement CI
Optimi Health Says Achieved Genetics Milestone and Completed Psilocybin Extract Validation and Stability Testing MT
Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing CI
Optimi Health Corp. Announces Executive Changes CI
Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial CI
3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023. CI
492,000 Warrants of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023. CI
606,000 Options of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023. CI
Optimi Health Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Optimi Health Corp. Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent CI
Optimi Health Corp. Announces Receipt of Purports Termination Notice CI
Chart Optimi Health Corp.
More charts
Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable psychedelic formulations for transformational human experiences. Its products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. It is a supplier of drug and nutraceutical products. The Company works with customers, health food distributors, and drug developers, and patients regulated by Health Canada.
More about the company
  1. Stock Market
  2. Equities
  3. OPTI Stock
  4. News Optimi Health Corp.
  5. Optimi Health Enters Supply Agreement with Halucenex Life Sciences